Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
idTracker: tracking individuals in a group by automatic identification of unmarked animals
Ida Mann Lecture 2007: Planet Eye
Idaein chloride induced p53 dependent apoptosis in cervical cancer cells through inhibition of viral oncoproteins
Idahelops alpagutae (Coleoptera: Tenebrionidae: Helopini): a new genus and species from the Aegean region of Turkey
Idalopirdine for Alzheimer's disease: written in the stars
Idalopirdine - a small molecule antagonist of 5-HT6 with therapeutic potential against obesity
Idala: An unnamed Function Peptide Vaccine for Tuberculosis
Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis
Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression
Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia
Idarucizumab for Dabigatran Reversal
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)
Idarucizumab The Antidote for Reversal of Dabigatran
Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran
Idarubicin-Loaded ONCOZENE Drug-Eluting Embolic Agents for Chemoembolization of Hepatocellular Carcinoma: In Vitro Loading and Release and In Vivo Pharmacokinetics
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome
Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study
Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective, Multicenter Study in Korea
Idarubicin is a broad-spectrum enterovirus replication inhibitor that selectively targets the virus internal ribosomal entry site
Idarucizumab for dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome
Idarucizumab for dabigatran overdose
Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation
Idarucizumab for dabigatran reversal - Does one dose fit all?
Idarubicin induces mTOR-dependent cytotoxic autophagy in leukemic cells
Idarucizumab for the Reversal of Dabigatran
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia
Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence
Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia
Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures
Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke
Idarucizumab since FDA approval: Use in the real-world
Idarucizumab (Praxbind) for Reversal of Pradaxa Prior to Emergent Repair of Contained Ruptured Transverse Arch Aneurysm
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects
Idarucizumab: First Global Approval
Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report
Idarucizumab: A Review as a Reversal Agent for Dabigatran
Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers
Idarucizumab: What Should We Know?
Idarucizumab-facilitated intravenous thrombolysis in acute stroke with dabigatran: Two cases with hemorrhagic transformation
Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease
Idas, a Novel Phylogenetically Conserved Geminin-related Protein, Binds to Geminin and Is Required for Cell Cycle Progression
Idazoxan attenuates spinal cord injury by enhanced astrocytic activation and reduced microglial activation in rat experimental autoimmune encephalomyelitis
Idazoxan reduces blood-brain barrier damage during experimental autoimmune encephalomyelitis in mouse
Ida~(2-)-H_2O体系浸出低品位氧化锌矿(英文)
Ida~(2-)-H_2O体系中氧化锌矿的循环浸出低品位
Idd Loci Synergize to Prolong Islet Allograft Survival Induced by Costimulation Blockade in NOD Mice
Idd13 is involved in determining immunoregulatory DN T-cell number in NOD mice
Idd9.2 and Idd9.3 Protective Alleles Function in CD4(+) T-Cells and Nonlymphoid Cells to Prevent Expansion of Pathogenic Islet-Specific CD8(+) T-Cells
Idd9.1 Locus Controls the Suppressive Activity of FoxP3(+)CD4(+)CD25(+) Regulatory T-Cells
Idd9/11 Genetic Locus Regulates Diabetogenic Activity of CD4 T-Cells in Nonobese Diabetic (NOD) Mice
Iddm30 Controls Pancreatic Expression of Ccl11 (Eotaxin) and the Th1/Th2 Balance within the Insulitic Lesions
Iddm1 and Iddm2 Homozygous WOK.4BB Rats Develop Lymphopenia, but no Hyperglycemia like the BB/OK Rats
IdeE reduces the bactericidal activity of equine neutrophils for Streptococcus equi
IdeE, an IgG-endopeptidase of Streptococcus equi ssp equi
IdeR is required for iron homeostasis and virulence in Mycobacterium tuberculosis
IdeS: A Bacterial Proteolytic Enzyme with Therapeutic Potential
IdeS and SpeB: immunoglobulin-degrading cysteine proteinases of Streptococcus pyogenes